Human Papillomavirus Genotype-Specific Prevalence Across the Continuum of Cervical Neoplasia and Cancer

Human Papillomavirus Genotype-Specific Prevalence Across the Continuum of Cervical Neoplasia and Cancer

1. Nancy E. Joste1, 
2. Brigitte M Ronnett2, 
3. William Curtis Hunt3, 
4. Amanda Pearse4,
5. Erika Langsfeld4, 
6. Thomas Leete4, 
7. MaryAnn Jaramillo4, 
8. Mark H. Stoler5,
9. Philip E. Castle6, 
10. Cosette M. Wheeler7,*, and
11. New Mexico HPV Pap Registry Steering Committee8

+Author Affiliations

1. ¹Pathology, University of New Mexico Health Sciences Center
2. ²Gynecologic Pathology, Johns Hopkins University
3. ³Department of Pathology and Department of Obstetrics and Gynecology, University of New Mexico
4. ⁴Pathology, University of New Mexico
5. ⁵Dept Pathol, Univ Virginia Hlth Sci
6. ⁶n/a, Global Cancer Initiative
7. ⁷Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center
8. ⁸n/a

1. ↵* Corresponding Author:
   Cosette M. Wheeler, Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, 1816 Sigma Chi Rd NE, Albuquerque, NM, 87131, United States CWheeler@salud.unm.edu

Abstract

Background. The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Prior to widespread HPV vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer. Methods. A population-based sample of 6,272 tissue specimens were tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines. Results. The combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3% and 29.3% in CIN1 to 58.4% and 83.7% in CIN3, respectively. The prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma, most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers. Conclusions. Health economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence. Impact. Population-based HPV prevalence in CIN is not well described but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.

• Received July 10, 2014.
• Revision received September 24, 2014.
• Accepted October 15, 2014.

• Copyright © 2014, American Association for Cancer Research.